Haemophilus influenzae polysaccharide vaccine

There are a number of practical problems involved with using polysaccharides as vaccines as there are frequently too many different chemotypes for it to be practicable to prepare a vaccine. In some cases a limited number of serotypes are the dominant cause of infection and it may then be possible to produce vaccines. A major problem is the poor immune response elicited by polysaccharide antigens, which may in some cases be improved by chemical modification. This is (fie case for vaccines for Haemophilus influenzae type b (a causative agent of meningitis), where the antigenicity of the polysaccharide can be increased by coupling to proteins. 

V. Verez-Bencomo, V. Femandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, A. Villar, Y. Valdes, et al., A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b, Science, 305 (2004) 522-525. 

Haemophilus influenzae type b (Hib) vaccines currently in use are conjugate products, consisting of either a polysaccharide or oligosaccharide of polyribosylribitol phosphate (PRP) covalently linked to a protein carrier. 

A further type of vaccine included in the subunit category is the capsular polysaccharide vaccines, for example, those against Haemophilus influenzae and meningococcal meningitis. In this case an extract of the polysaccharide outer capsule of the bacterium is used as a vaccine and is sometimes conjugated to protein to... 

Each lyophilisate for one immunising dose of diphtheria, tetanus toxoids and pertussis with Haemophilus b conjugate vaccine contains Haemophilus influenzae type b polysaccharide conjugated to tetanus protein 10 meg, purified diphtheria toxoid 1 immunising dose, purified tetanus toxoid 1 immunising dose, Bordetella pertussis minimum of 4.1 lU. 

Kayhty, H., V. Karanko, H. Peltola, and P.H. Makela, Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization no evidence of immunologic tolerance or memory. Pediatrics, 1984. 74(5) 857-65. 

A sulfur-based chemoselective method was applied to the synthesis of a conjugate polysaccharide vaccine against Haemophilus influenzae type b.37 The... 

Werz DB and Seeberger PH. Carbohydrates as the next frontier in pharmaceutical research. Chem Eur J, 2005 11(11) 3194-3206. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004 305 522-525. 

Kanra, G. Yurdakok, K. Ceyhan, M. Ozmert, E. Turkay, F. Pehlivan, T. Immunogenicity and safety of haemophilus influenzae type B capsular polysaccharide tetanus conjugate vaccine (PRP-T) presented in a dualchamber syringe with DTP. Acta Paediatr. Jpn. 1997, 39, 676-680. 

Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr 1988 113(4) 621-31. 

Capsular polysaccharide of bacteria is one of the significant targets for development of vaccines [128]. For example, Haemophilus influenza type B (Hib) vaccine, made of a polysaccharide-protein conjugate, is now used worldwide as a highly effective therapy [129]. Verez-... 

Some examples of research under development include a synthetic conjugated polysaccharide vaccine against Haemophilus influenzae type B, which has been described in 2004 (O Fig. 34). The vaccine prototype was obtained by conjugation to human serum albumin (HSA) [173]. Furthermore, very recently a malaria vaccine has been suggested [174] which is based on the total synthesis of the malaria toxin responsible for the morbidity and mortality associated with malaria. The malaria parasite expresses a large amount of glycosylphosphatidylinositol... 

Polysaccharide vaccine Conjugate vaccine Meningitis Pneumonia Haemophilus influenzae typeb... 

As polysaccharide vaccines were shown to elicit only limited protection in infants and young children, conjugated polysaccharide vaccines were developed to provide a more potent and sustained immune response [2]. Many of these traditional vaccines target childhood diseases, and are used in combinations for pediatric applications in order to reduce the number of injections during the first years of life. Currently, vaccine combinations can prevent against between three to six different diseases, such as the measles-mumps-rubella (MMR) vaccine or the diphtheria-tetanus-pertussis combination, which may be administered together with Haemophilus influenzae, hepatitis B, or poliovirus vac-... 

A polysaccharide vaccine made from Haemophilus influenzae is a poor vaccine in very young children, where the disease threat is maximum. The vaccine is also poor in young monkeys. Table 5 shows this. The data presented are normalized values, obtained by radioimmune assays done by Dr. Porter Anderson (Levy et al., 1980). 

Table 5. Effect of Low Doses of Poly(ICIC) on Antibody Production by Rhesus Monkeys in Response to a Polysaccharide Vaccine for Haemophilus influenzae...

---